Language

English

Publication Date

9-1-2025

Journal

European Journal of Obstetrics & Gynecology and Reproductive Biology

DOI

10.1016/j.ejogrb.2025.114650

PMID

40816247

PMCID

PMC12424477

PubMedCentral® Posted Date

9-12-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Background: Nearly three-quarters of women experience heavy menstrual bleeding (HMB) during anticoagulation treatment for venous thromboembolism (VTE). HMB can lead to medical interventions, impact school or work and diminish quality of life (QOL). While there are several management options for HMB in patients with VTE, we lack information on how patients approach HMB treatment decisions.

Objectives: We examined patients' experience with, perceptions of, and preferences for treatment of HMB while on anticoagulation.

Methods: Clinicians and patient advocates developed a web-based survey that was distributed via patient advocacy organizations and social media between May and June 2024, targeting participants 18 years or older who menstruate with a history of VTE and self-reported HMB.

Results: A total of 387 participants completed the survey. All participants (100%) reported a history of HMB, and half (50%) experienced HMB while on anticoagulation for greater than twelve months. The majority (86%) reported a negative effect on their QOL. Only 43% of patients reported receiving treatment for HMB, with 10% reporting temporarily holding anticoagulation due to HMB. Approximately a fifth of respondents associated low-risk treatment modalities with thrombosis, including progesterone-only oral contraceptives (21%), implants (18%), and intrauterine devices (progesterone 18%, copper 17%). The majority (83%) of patients identified thrombotic risk as the most important factor when considering treatment options.

Conclusions: HMB is under-reported and undertreated in patients on anticoagulation. Patients have important misconceptions about treatment options; prioritized recurrent thrombosis risk when weighing treatment options; and preferred a multidisciplinary, multimodal approach. These findings should inform interventions to improve patient education and decision support for HMB on anticoagulants.

Keywords

Humans, Female, Menorrhagia, Anticoagulants, Adult, Middle Aged, Venous Thromboembolism, Surveys and Questionnaires, Patient-Centered Care, Quality of Life, Young Adult, Patient Preference, Adult, anticoagulants, contraceptives, female, humans, intrauterine devices, menorrhagia, progesterone, quality of life, thrombosis, venous thromboembolism

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.